Tigecycline: its potential for treatment of brucellosis.
The in vitro efficacy and synergistic activity of tigecycline in comparison with other antimicrobials used in brucellosis, were tested for 16 Brucella melitensis strains by the E-test method. Tigecycline had the lowest minimal inhibitory concentration levels, and rifampin the highest, in the study. Tigecycline also provided the better synergistic activity compared to doxycycline according to the fractional inhibitory concentration index. The results of this in vitro study suggest tigecycline as a therapeutic alternative for brucellosis. These observations need to be supported with clinical studies.
Dizbay
Murat
M
Department of Clinical Microbiology and Infectious Diseases, Gazi University School of Medicine, Ankara, Turkey. muratdizbay@gazi.edu.tr
Kilic
Selcuk
S
Hizel
Kenan
K
Arman
Dilek
D
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D017347:Brucella melitensis / Q000187:drug effects*; D002006:Brucellosis / Q000188:drug therapy*; D004318:Doxycycline / Q000494:pharmacology; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006801:Humans; D008826:Microbial Sensitivity Tests; D008911:Minocycline / Q000031:analogs & derivatives* / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D013307:Streptomycin / Q000494:pharmacology; D000078304:Tigecycline
D000900:Anti-Bacterial Agents; D000078304:Tigecycline; D008911:Minocycline; D004318:Doxycycline; D012293:Rifampin; D013307:Streptomycin